BFIM
SGMO

Beese Fulmer Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Beese Fulmer Investment Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$9K – 478
2020
Q2 		$9K Buy
+1,000
New +$9.28K ﹤0.01% 486

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Beese Fulmer Investment Management's SGMO Position: Q3 2020 in Review

Beese Fulmer Investment Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2020, closing a stake of 1,000 shares — an estimated $9K sold.

Beese Fulmer Investment Management first reported a position in SGMO in Q2 2020 and held it in 1 quarter. The position peaked at $9K in Q2 2020. 210 funds tracked by Wall St. Rank hold SGMO as of Q3 2020.

  • Beese Fulmer Investment Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2020 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 1,000 SANGAMO THERAPEUTICS INC shares in Q3 2020, an estimated $9K.
  • Beese Fulmer Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2020 and held it in 1 quarter.
  • Beese Fulmer Investment Management's SANGAMO THERAPEUTICS INC position peaked at $9K in Q2 2020.
  • 210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2020.

Based on Beese Fulmer Investment Management's 13F filing for Q3 2020, filed 8 Oct 2020.